

Supplementary Material

Effect of food consumption on the pharmacokinetics, safety, and tolerability of orforglipron (LY3502970), an orally administered non-peptide GLP-1 receptor agonist

Authors

Xiaosu Ma, PhD¹, Rong Liu, PhD¹, Edward J. Pratt, MD¹, Charles T. Benson, MD, PhD¹, Shobha N. Bhattachar, MS¹, Kyle W. Sloop, PhD¹

Affiliations

¹ Eli Lilly and Company, Indianapolis, IN, USA

Corresponding author: Xiaosu Ma, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46240, USA; E-mail: ma_xiaosu@lilly.com

Table S1: Treatment-emergent Adverse Events in Studies A and B

MedDRA preferred term	Study A OFG 3 mg	
	Fasted (N=12)	Fed (N=12)
Nausea	2 (16.7)	0 (0.0)
Abdominal pain upper	1 (8.3)	0 (0.0)
Dizziness	1 (8.3)	0 (0.0)
Headache	1 (8.3)	0 (0.0)
Oropharyngeal pain	1 (8.3)	0 (0.0)
Sneezing	1 (8.3)	0 (0.0)
Vomiting	1 (8.3)	0 (0.0)
	Study B OFG 16 mg	
	Fasted (N=28)	Fed (N=27)
Nausea	4 (14.3)	5 (18.5)
Abdominal distension	4 (14.3)	3 (11.1)
Headache	4 (14.3)	2 (7.4)
Catheter site erythema	3 (10.7)	3 (11.1)
Decreased appetite	3 (10.7)	1 (3.7)
Vomiting	2 (7.1)	2 (7.4)
Diarrhea	2 (7.1)	2 (7.4)
Eructation	2 (7.1)	1 (3.7)
Catheter site bruise	1 (3.6)	2 (7.4)
Dizziness	0 (0.0)	2 (7.4)
Erythema	1 (3.6)	1 (3.7)
Dry mouth	1 (3.6)	0 (0.0)
Dyspepsia	1 (3.6)	0 (0.0)
Abdominal pain	0 (0.0)	1 (3.7)
Catheter site infection	0 (0.0)	1 (3.7)
Catheter site phlebitis	1 (3.6)	0 (0.0)
Constipation	1 (3.6)	0 (0.0)
Lethargy	1 (3.6)	0 (0.0)
Catheter site pain	0 (0.0)	1 (3.7)

Data are presented as n (%)

Abbreviations: N = total number of participants; n = number of participants; OFG = orforglipron